恩度联合化疗治疗晚期非小细胞肺癌的临床观察

目的评价重组人血管内皮抑制度（恩度）联合化疗治疗晚期非小细胞肺癌的疗效和不良反应。方法121例晚期非小细胞肺癌患者，按随机数字表法分成两组，其中58例恩度联合化疗治疗f试验组）；63例仅接受化疗（对照组）。观察两组的近期总有效率、临床获益率和疾病进展时间。结果试验组总有效率37．93％（22／58），对照组为19．05％（12／63），两组比较差异有统计学意义（P〈0．05）；试验组临床获益率为81．03％（47／58），对照组为63．49％（40／63），两组比较差异有统计学意义（P〈0．05）；试验组的中位疾病进展时间为7．9个月，对照组为6-3个月（P〈0．05）。试验组每个周期的药物不良反应发生率与对照组发生率的比较差异无统计学意义（P〉0．05）。结论恩度联合化疗治疗晚期非小细胞肺癌临床疗效显著，可延长疾病进展时间，耐受性好，值得临床推广应用。

Clinical observation on recombinant human endostain combined with chemotherapy in advanced non-small cell lung cancer

Objective To investigate effect and safety of recombinant human endostain（rhendostatin） combined with chemotherapy in advanced non-small cell lung cancer. Methods Divided 121 patients with histologically diagnosed advanced non-small cell lung cancer into two groups. The study group（receiving rh-endostatin combined with chemotherapy） had 58 patients and control group （receiving chemotherapy only） had 63 patients. The short-term response rate（RR）, clinical benefit rate（CBR） and time to progression（TTP） were evaluated. Results The short-term response rate（RR） in study group was 37.93%（22/58）, while in the control group was 19.05%（12/63）（P〈0.05）. The clinical benefit rate （CBR） in study group was 81.03%（47/58）, while in the control group was 63.49%（40/63）（P〈0.05）. The TTP was 7.9 months in study group, while which was 6,3 months in the control group, there was a significant difference between the two groups（P〈0.05）. There was no statistical difference in adverse effect between the two groups （P〉0.05）. Conclusion The combination of rh-endostatin and chemotherapy may lead to a better short-term RR and prolong TTP without increasing toxieities.